Revance Therapeutics Inc (RVNC)

[soma2022]

I feel Daxi pricing and messaging have improved greatly and injectors are gradually figuring out the injection pattern, managing patient expectations, and gaining confidence in the sales pitch. Sales reps and management are reengaging with injectors in a more positive, generous, and humble manner. It is now time for Daxi sales to grow. Focusing on the past or what should have been done is a waste of time now. The share price more than takes those mistakes into account, and the financing should be done if they are right about cash flow break even by 2025.